

Section 708A(5)(e) disclosure notice – issue of shares by Tissue Therapies Limited (Issuer) (ASX Code: TIS)

The Company relies upon case 1 in section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**) in respect of the placement of shares to Mr Geoff Morris (or his nominee) as set out in the Appendix 3B dated 21 June 2011. As required by section 708A(6) *Corporations Act*, the Issuer named above notifies ASX, the operator of the prescribed financial market, of details about the issue of securities by placement to Mr Geoff Morris, in this notice.

Details of the securities issued

Class of securities:	Fully paid ordinary shares
ASX Code of the securities:	TIS
Date of the issue or expected issue of the securities:	21 June 2011
Total number of securities issued or expected to be issued:	55,511

Signed for the Issuer:

Date: 21 June 2011	Name: Steven Mercer	Position held: Managing Director
	Signature: Original signed	

- 1 The above securities will be, or have been, issued without disclosure to investors under section 708A(6) of part 6D.2 *Corporations Act* and as permitted in compliance with section 708A.
- 2 This notice is given under section 708A(5)(e) and in accordance with section 708A(6) *Corporations Act*.
- 3 At the date of this notice, the Issuer has complied with the provisions of Chapter 2M *Corporations Act* (as modified by an ASIC declaration dated 1 July 2004) in application to the Issuer and the Issuer has complied with section 674 *Corporations Act*.
- 4 There is no 'excluded information' required to be set out in this notice under sections 708A(7) and (8) *Corporations Act*.

- 5 The securities referred to above are ordinary shares in a class of securities that were ASX quoted securities, within the meaning of section 708A(5) Corporations Act, at all times in the three months before the day on which the relevant securities were issued.
- 6 The securities referred to above have been trading on ASX in circumstances where trading has not been suspended for more than a total of five days during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.
- 7 No exemptions under sections 111AS or 111AT Corporations Act cover the Issuer or any person as director or auditor of the Issuer at any time during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.
- 8 Except as modified by the ASIC declaration of 1 July 2004, no order under sections 340 or 341 Corporations Act covers the Issuer or any director or auditor of the Issuer at any time during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute for Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com

Tissue Therapies Limited ABN 45 101 955 088 www.tissuetherapies.com
6th Floor, Institute of Health & Biomedical Innovation
60 Musk Ave
Kelvin Grove QLD 4059 Australia
GPO Box 1596 Brisbane Qld 4001
telephone +61 7 3839 9938 facsimile +61 7 3839 1486